Skip to main content
. 2016 Nov 2;11(2):203–211. doi: 10.1007/s12105-016-0765-y

Table 1.

Clinical and pathologic features stratified by PD-L1 expression. Positive PD-L1 expression is defined as 1% or more tumor cells with membranous PD-L1 staining

Total N = 56 PD-L1−
N = 20
PD-L1+
N = 36
P
Mean age (year, [median, range]) 48.7 (48.5, 19–71) 48.9 (49.0, 19–67) 48.6 (48.0, 24–71) 0.995
Sex (n, [%])
 Female 13 (23) 4 (20) 9 (25) 0.752
 Male 43 (77) 16 (80) 27 (75)
pT (n, [%])
 T1 17 (30) 8 (40) 9 (25) 0.541
 T2 16 (29) 4 (20) 12 (33)
 T3 12 (21) 5 (25) 7 (19)
 T4 11 (20) 3 (15) 8 (22)
pN (n, [%])
 pN0 22 (39) 6 (30) 16 (44) 0.476
 pN1 27 (48) 11 (55) 16 (44)
 pN2 4 (7) 1 (5) 3 (8)
 pN3 3 (5) 2 (10) 1 (3)
pM (n, [%])
 pM0 49 (88) 17 (85) 32 (89) 0.691
 pM1 7 (12) 3 (15) 4 (11)
Stage (n, [%])
 Stage I 11 (20) 3 (15) 8 (22) 0.879
 Stage II 16 (29) 7 (35) 9 (25)
 Stage III 12 (21) 4 (20) 8 (22)
 Stage IV 17 (30) 6 (30) 11 (31)
Total follow-up time (month, mean [median, range]) 51.3 (51.5, 14–88) 47.5 (49.5, 14–71) 53.5 (52.5, 31–88) 0.297
Treatment (n, [%])
 Radiation 2 (4) 1 (5) 1 (3) 1.000
 Chemotherapy and radiation 54 (96) 19 (95) 35 (97)
Tobacco use (n, [%])a N = 46 N = 18 N = 28
 Non-smoker 32 (70) 9 (50) 23 (82) 0.047
 Smoker 14 (30) 9 (50) 5 (18)
Alcohol use (n, [%])a N = 46 N = 18 N = 28
 Non-drinker 30 (65) 10 (56) 20 (71) 0.215
 Drinker 16 (35) 8 (44) 8 (29)

aEither tobacco or alcohol usage was unknown for 10 patients